Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Current Deferred Revenue (2022 - 2025)

Goldenwell Biotech's Current Deferred Revenue history spans 4 years, with the latest figure at $37500.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 3030.22% year-over-year to $37500.0; the TTM value through Sep 2025 reached $37500.0, up 3030.22%, while the annual FY2024 figure was $1860.0, 2.82% down from the prior year.
  • Current Deferred Revenue reached $37500.0 in Q3 2025 per GWLL's latest filing, down from $62500.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $62500.0 in Q2 2025 to a low of $1198.0 in Q1 2024.
  • Average Current Deferred Revenue over 4 years is $9572.3, with a median of $1410.0 recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: decreased 15.04% in 2024, then skyrocketed 5117.03% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $1410.0 in 2022, then surged by 35.74% to $1914.0 in 2023, then dropped by 2.82% to $1860.0 in 2024, then soared by 1916.13% to $37500.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Current Deferred Revenue are $37500.0 (Q3 2025), $62500.0 (Q2 2025), and $1860.0 (Q1 2025).